RA 101495

Drug Profile

RA 101495

Alternative Names: RA101495; RA101495 SC

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ra Pharmaceuticals
  • Class Cyclic peptides; Macrocyclic compounds
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Lupus nephritis

Most Recent Events

  • 12 Feb 2018 Ra Pharmaceuticals plans a registrational phase III trial for Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in 2H 2018
  • 12 Feb 2018 Updated adverse events data from a phase II trial in Paroxysmal nocturnal hemoglobinuria released by Ra Pharmaceuticals
  • 12 Feb 2018 Ra Pharmaceuticals completes enrolment in its phase II trial in Paroxysmal nocturnal haemoglobinuria in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top